Joshua Higa | Head of Investor Relations |
Emil Kakkis | Founder, President and Chief Executive Officer |
Erik Harris | Executive Vice President and Chief Commercial Officer |
Camille Bedrosian | Executive Vice President and Chief Medical Officer |
Aaron Olson | SVP, Corporate Strategy and Finance |
Ted Hazinga | Chief Accounting Officer |
Gena Wang | Barclays |
Chris Raymond | Piper Sandler |
Joon Lee | Truist Securities |
Yigal Nochomovitz | Citi Research |
Tazeen Ahmad | Bank of America |
Jeff Hung | Morgan Stanley |
Maury Raycroft | Jefferies LLC |
Dae Gon Ha | Stifel |
Liisa Bayko | Evercore |
Anupam Rama | JPMorgan |
Joel Beatty | R W. Baird |
Good afternoon, and welcome to the Ultragenyx Fourth Quarter and Full Year 2022 Financial Results Conference Call. [Operator Instructions] It is now my pleasure to turn the call over to Joshua Higa, Executive Director and Head of Investor Relations.
Thank you.
We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com.
Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Erik Harris, Chief Commercial Officer; Camille Bedrosian, Chief Medical Officer; Aaron Olson, Senior Vice President of Corporate Strategy and Finance; and Ted Hazinga, Chief Accounting Officer.